Please assess the completion status of the following clinical trial:

Trial Title: A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of refractory epilepsy~* Patients must be receiving a stable dose of 1 - 3 concomitant Anti-Epileptic Drugs (AED)~* Female patients without childbearing potential. Female patients with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method~Exclusion Criteria:~* Seizures occurring in clusters~* Status epilepticus within 3 months of Visit 1~* History of non-epileptic seizures~* Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients~* Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, non-hormonal method of birth control

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Keppra® XR (Type: EXPERIMENTAL): Keppra® extended release formulation -XR
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).